|Videos|October 20, 2017
Dr. Karmali Discusses Toxicites Associated With CAR T-Cell Therapies
Author(s)Reem Karmali, MD
Reem Karmali, MD, assistant professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses the toxicities associated with the use of chimeric antigen receptor (CAR) T-cell therapies.
Advertisement
Reem Karmali, MD, assistant professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses the toxicities associated with the use of chimeric antigen receptor (CAR) T-cell therapies.
There are 2 main toxicities that experts are worried about, says Karmali—cytokine release syndrome and neurotoxicity. It is not yet clear what the mechanism is for neurotoxicity.
Karmali says that the patients being selected should have relatively preserved organ function so that they can withstand these toxicities.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Related Articles
Annaiz Grimm, BS, on Using EngTregs to Treat Autoimmune DiseaseAugust 28th 2025
